Bio-Me news
The Microbiome Therapeutics Innovation Group (MTIG) today announced the addition of Bio-Me to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products.
Bio-Me offers a wide range of proprietary solutions to facilitate the gut microbiome analysis process for academia and pharma researchers and is setting the standard for next-generation routine microbiome analysis with its Precision Microbiome Profiling (
Microbiome precision medicine company Bio-Me today announced that Dr. Warren Flood has become CEO following his successful period as COO. Previous CEO Dr. Morten Isaksen moves up to the Board and will also continue as Chief Innovation Officer with a focus on longer term and higher-value clinical applications for the company’s Precision Microbiome Profiling (PMP™) technology. These steps are part of the company’s strategic plan to position Bio-Me as a leader in microbiome-bas
On September 22nd Warren Flood, Ph.D. and COO of Bio-Me, will participate in a webinar organized together with Thermo Fisher Scientific with the title “Missing a piece of the puzzle? Factor in the gut microbiome”. There, he will present how our PMP platform, based on Thermo Fisher Scientific’s OpenArray qPCR technology, helps researchers and industry translating their gut microbiome discoveries into future solutions and applications.
On July 1st Bio-Me has two back-to-back presentations. Our Founder and CEO, Morten L. Isaksen will first be presenting how we support companies in their development of microbiome modulating drugs with our PMP™ technology for targeted microbiome analysis. Following that, our COO Warren Flood will do a joint presentation with Ricardo Valladares, CSO at Siolta Therapeutics showcasing how we work together to facilitate their drug development in infant allergic
Bio-Me today announced a major board restructuring with Carl Christian Glilhuus-Moe stepping up to the Executive Chair position. He is joined by new board members Hilde Furberg, Anne-Marie Duus Kristensen, and Arne Materna who collectively bring a wealth of diagnostic, microbiology, and commercialization experience as the Company enters a new phase of development following a recent succes